Methods of using butyrophilin antibodies for treating hiv infection
AssigneeMerck Sharp & Dohme Corp.
InventorsBonnie Jean Howell, Hsien-Wei Yvonne Meng, Morgan Ann Monslow, Hussam Hisham Shaheen, Sai Vikram Vemula
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating individuals infected with the human immunodeficiency virus (HIV) comprising administering to the subject with an antibody to Butyrophilin that reactivates HIV from latency and/or activates CD4+ T cells.
Claims13
A method of treating HIV in a subject comprising the step of administering to the subject a therapeutically effective amount of an antagonist anti-Butyrophilin3A (BTN3A) antibody, wherein the antibody activates CD4+ T cells and reactivates HIV from latency.
A method of reactivating HIV from latency in a subject comprising the step of administering to the subject a therapeutically effective amount of an antagonist anti-Butyrophilin3A (BTN3A) antibody, wherein the antibody reactivates HIV from latency.
A method of treating HIV in a subject, said method comprising the step of administering to the subject a therapeutically effective amount of an antagonist anti-Butyrophilin3A (BTN3A) antibody.
A method of treating HIV in a subject comprising the step of administering to the subject a therapeutically effective amount of an antagonist anti-Butyrophilin3A (BTN3A) antibody, wherein the antibody activates CD4+ T cells.
Dependencies are inferred from the claim text.